Monte Rosa Therapeutics (GLUE) Total Current Liabilities (2020 - 2026)

Monte Rosa Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $71.0 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 19.96% year-over-year to $71.0 million in Q1 2026; TTM through Mar 2026 was $71.0 million, a 19.96% increase from a year earlier, with the FY2025 full-year figure at $64.2 million, down 59.09% from the prior year.
• Total Current Liabilities climbed to $71.0 million in Q1 2026 per GLUE's latest filing, from $64.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $156.9 million in Q4 2024 and bottomed at $12.5 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $41.6 million (2024), against an average of $44.9 million.
• Across the five-year window, Total Current Liabilities surged 236.85% in 2024 and sank 59.09% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $25.6 million in 2022, then soared by 82.22% to $46.6 million in 2023, then jumped by 236.85% to $156.9 million in 2024, then sank by 59.09% to $64.2 million in 2025, then advanced by 10.63% to $71.0 million in 2026.
• Per Business Quant, the three latest GLUE Total Current Liabilities figures stand at $71.0 million (Q1 2026), $64.2 million (Q4 2025), and $61.4 million (Q3 2025).